Teva Pharmaceutical

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The firm operates through following geographical segments: North America, Europe and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teva Pharmaceutical reports robust Q4 earnings, eyes biosimilar growth

Teva Pharmaceutical's Q4 2022 performance showcased revenue growth, strong product momentum, and strategic initiatives in biosimilars and legal settlements. While challenges in debt reduction and market dynamics persist, the company's focus on growth opportunities and financial targets provides a positive outlook for stakeholders.

Teva Pharmaceutical reports revenue growth amidst biosimilar setbacks and opportunities

Teva's Q1 2023 showcased revenue growth, particularly in innovative products like AUSTEDO and AJOVY.
Despite challenges in the biosimilar pipeline and financial losses, the company remains focused on strategic initiatives.
Opportunities lie in UZEDY's market potential and capital allocation for growth and profitability.
Gross margin pressures and legal settlements add complexity to Teva's path forward, requiring careful management.

Teva Pharmaceutical reports Q2 growth, navigates challenges, eyes expansion

Teva Pharmaceutical's Q2 2023 earnings call highlighted revenue growth, operational strength, and commitment to ESG goals, despite facing GAAP losses and operational challenges.
With a focus on debt reduction, increased revenue outlook, and strategic opportunities in biosimilars and new markets, Teva aims to drive long-term growth and financial stability.
Analysts' questions on patient outreach, asset divestiture, and EU entry underscore areas for improvement, while progress on AUSTEDO and UZEDY reception signal positive momentum.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Executive Vice President & CFO Eli Kalif will present at the J.P. Morgan 2021 Global High Yield and Leveraged Finance Conference on Tuesday, March 2, 2021 at 8:30 a.m. Eastern Time. To access a live webcast of the presentation, visit Teva's Investor Relations website at https://ir.tevapharm.com/Events-and-Presentations/events-and-presentations/default.aspx An archived version of

Teva to Present at the J.P. Morgan 2021 Global High Yield and Leveraged Finance Conference

PG&E

Zoom Video

Etsy

South Korea's National Pension Service started investments in PG&E and Etsy, bought more Zoom stock, and sold most of its Teva position in the fourth quarter.

A Giant Pension Bought Up PG&E, Zoom, and a Stock Elon Musk Loves

The largest generic drug manufacturer in the world can be bought for pennies on the dollar.

Is Teva Pharmaceuticals a Safe Stock to Buy Now?

TEVA beats on fourth-quarter earnings and sales. It issues its financial guidance for 2021.

TEVA Stock Declines Despite Q4 Earnings and Sales Beat

Big 5 Sporting Goods

Cloudera

CarParts.com, Inc.

SSR Mining

Sunopta

Even though the market has been on fire recently, that doesn't mean you're too late to pick up cheap stocks under $20 with 2x (or more) potential. The post 8 Cheap Stocks Under $20 That Could Double appeared first on InvestorPlace.

8 Cheap Stocks Under $20 That Could Double

Teva Pharmaceutical Industries Limited (TEVA) CEO Kåre Schultz on Q4 2020 Results - Earnings Call Transcript

TEVA beats earnings and sales for fourth-quarter 2020. It issues its financial guidance for 2021.

TEVA Q4 Earnings & Sales Beat Estimates, Stock Rises

Shares of Teva Pharmaceutical Industries Ltd. gained 2.7% in premarket trading on Wednesday after the drugmaker beat expectations for revenue and adjusted earnings per share in the final quarter of 2020.

Teva's stock rallies 2% on earnings

Shares of Teva Pharmaceutical Indus (NYSE:TEVA) moved higher by 3.7% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 9.68% over the past year to $0.68, which beat the estimate of $0.63.

Recap: Teva Pharmaceutical Q4 Earnings

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the year and the quarter ended December 31, 2020. Q4 2020 and FY 2020 highlights:   Q4 2020 FY 2020 Revenues   $4.5 billion $16.7 billion Cash flow from operating activities   $331 million $1,216 million Free cash flow   $471 million $2,110 million GAAP earnings (loss) per share   $0.14 $(3.64) Non-GAAP EPS   $0.68 $2.57 2021 business outlook: Revenues are expected to be $16.4

Teva Reports Fourth Quarter and Full Year 2020 Financial Results

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Should Value Investors Buy Teva Pharmaceutical Industries Ltd. (TEVA) Stock?

On TEVA's fourth-quarter conference call, investors focus is likely to be on updates on the extent to which the resurgence of COVID-19 infection rates impacted sales of its products.

TEVA Gears Up to Report Q4 Earnings: What's in the Cards?

Kirkland Lake Gold

Walgreens

Things are looking up for these beaten-down value plays in the new year.

3 Turnaround Stocks That Will Make You Richer in 2021

The shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) are up 0.4% at $11.54 this morning, after the company announced plans to launch a generic version of Merck's (MRK) birth control device known as the NuvaRing®.

Teva Stock Pops on Generic NuvaRing® Announcement

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd.(NYSE and TASE: TEVA), today announced the availability of a generic version of NuvaRing®1 (etonogestrel and ethinyl estradiol vaginal ring), 0.120 mg/0.015 mg per day, in the U.S. Teva's AB-rated and bioequivalent etonogestrel and ethinyl estradiol vaginal ring, is an estrogen/progestin combination hormonal contraceptive (CHC) indicated for use by women t

Teva Announces Launch of a Generic Version of NuvaRing® (etonogestrel and ethinyl estradiol) Vaginal Ring in the United States

JPMorgan Chase & Co

Teva Pharmaceutical Industries Limited (TEVA) CEO Kåre Schultz on 39th Annual JP Morgan Healthcare Conference Transcript

Yamana Gold

Exelixis

Wells Fargo

Bargains are plentiful for value investors in the new year.

5 Value Stocks That Will Make You Richer in 2021

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter and full year 2020 financial results, as well as on its financial guidance for 2021, on Wednesday, February 10, 2021 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please dial the following numbers (at least 10 minutes before th

Teva to Host Conference Call to Discuss Fourth Quarter 2020 Financial Results and 2021 Financial Guidance at 8 a.m. ET on February 10, 2021

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that President & CEO Kåre Schultz will present at the 39th Annual J.P. Morgan Healthcare Conference in San Francisco, California on Wednesday, January 13, 2021. The presentation will begin at 8:20 A.M. Eastern Time. To access a live webcast of the presentation, visit Teva's Investor Relations website at http://ir.tevapharm.com. An archived version of the presentation will be availabl

Teva to Present at the 39th Annual J.P. Morgan Healthcare Conference

TEL AVIV, Israel & PARIS--(BUSINESS WIRE)--Teva Pharmaceuticals Industries Ltd. (NYSE and TASE: TEVA) and MedinCell (Euronext: MEDCL) today announced positive results for study TV46000-CNS-30072 (the RISE study – The Risperidone Subcutaneous Extended-Release Study), a Phase 3 clinical trial designed to evaluate the efficacy of TV-46000/mdc-IRM (risperidone extended-release injectable suspension for subcutaneous use) as a treatment for patients with schizophrenia. Trial enrollment was open to pa

Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia

Amazon

Barrick Gold

These time-tested Buffett holdings can pump up your portfolio.

5 Buffett Stocks to Buy Hand Over Fist in 2021

Coca-Cola

American Express

Warren Buffett stocks have been a mixed bag during this bull market. These four names are the weakest in Berkshire's portfolio.

4 Warren Buffett Stocks He Should Sell

EverBank Financial

Lovesac Company

OrganiGram Holdings Inc.

Triple-digit returns could be just a click of the buy button away.

8 Stocks That Could Double Your Money in 2021

First Majestic Silver

Pinterest

Teladoc

This Fool is counting on five growth and value stocks to power his portfolio higher in the new year.

My Top 5 Portfolio Holdings for 2021

There's something for every type of value investor.

News for Teva Pharmaceutical Stock (TEVA)